NASDAQ:CORI - Corium International Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $12.68 0.00 (0.00 %) (As of 12/13/2018 11:26 AM ET)Previous Close$12.68Today's Range$12.68 - $12.6852-Week Range$7.17 - $13.93VolumeN/AAverage Volume577,723 shsMarket Capitalization$459.65 millionP/E Ratio-7.73Dividend YieldN/ABeta0.87 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Corium International, Inc., a biopharmaceutical company, focuses on the development, manufacture, and commercialization of specialty pharmaceutical products in transdermal and transmucosal delivery systems. It offers Clonidine Transdermal Delivery System (TDS), a treatment for hypertension; Fentanyl TDS, a treatment for the management of chronic pain, including cancer-related pain; and Crest Whitestrips for teeth whitening. The company's products under pipeline comprise Twirla, a combination hormonal contraceptive patch, which has completed Phase III clinical trials to deliver ethinyl estradiol and levonorgestrel hormones; MicroCor hPTH(1-34), a transdermal system that has completed Phase 1 and Phase II a clinical trials for the treatment of severe osteoporosis; and Donepezil and Memantine transdermal systems, which completed Phase I clinical trials for the treatment of Alzheimer's disease. In addition, it develops Aripiprazole TDS for the treatment for psychiatric disorders; Corplex Ropinirole, a transdermal patch for the treatment of Parkinson's disease; and Motion Sickness Patch, a generic transdermal product for the prevention of nausea and vomiting associated with motion sickness. Corium International, Inc. has collaboration agreements with The Procter & Gamble Company; Teva Pharmaceuticals USA, Inc.; Agile Therapeutics, Inc.; and Aequus Pharmaceuticals, Inc. The company was incorporated in 1995 and is headquartered in Menlo Park, California. Receive CORI News and Ratings via Email Sign-up to receive the latest news and ratings for CORI and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CORI Previous Symbol CUSIPN/A Webwww.coriumgroup.com Phone650-298-8255 Debt Debt-to-Equity Ratio2.83 Current Ratio7.61 Quick Ratio7.47 Price-To-Earnings Trailing P/E Ratio-7.73 Forward P/E Ratio-8.23 P/E GrowthN/A Sales & Book Value Annual Sales$31.86 million Price / Sales14.43 Cash FlowN/A Price / Cash FlowN/A Book Value$0.45 per share Price / Book28.18 Profitability EPS (Most Recent Fiscal Year)($1.64) Net Income$-47,790,000.00 Net Margins-155.21% Return on Equity-276.89% Return on Assets-57.52% Miscellaneous Employees213 Outstanding Shares36,250,000Market Cap$459.65 million OptionableOptionable Corium International (NASDAQ:CORI) Frequently Asked Questions What is Corium International's stock symbol? Corium International trades on the NASDAQ under the ticker symbol "CORI." How were Corium International's earnings last quarter? Corium International Inc (NASDAQ:CORI) released its quarterly earnings results on Thursday, August, 9th. The biopharmaceutical company reported ($0.34) earnings per share for the quarter, topping analysts' consensus estimates of ($0.38) by $0.04. The biopharmaceutical company earned $7.67 million during the quarter, compared to analysts' expectations of $6.72 million. Corium International had a negative return on equity of 276.89% and a negative net margin of 155.21%. View Corium International's Earnings History. What price target have analysts set for CORI? 3 Wall Street analysts have issued 1-year price targets for Corium International's stock. Their predictions range from $13.00 to $14.00. On average, they anticipate Corium International's share price to reach $13.6667 in the next twelve months. This suggests a possible upside of 7.8% from the stock's current price. View Analyst Price Targets for Corium International. What is the consensus analysts' recommendation for Corium International? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Corium International in the last year. There are currently 2 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Corium International. What are Wall Street analysts saying about Corium International stock? Here are some recent quotes from research analysts about Corium International stock: 1. According to Zacks Investment Research, "Corium International, Inc. is a commercial-stage biopharmaceutical company. It is focused on the development, manufacture and commercialization of specialty pharmaceutical products that leverage advanced technologies in transdermal and transmucosal delivery systems. Corium has developed six marketed products in the prescription drug and consumer markets: Clonidine Transdermal Delivery System for hypertension, Fentanyl TDS for chronic pain and four Crest Advanced Seal Whitestrips products. The company has two proprietary transdermal technology platforms with applications in multiple drug categories and indications: Corplex(TM) and MicroCor(R). Corium International, Inc. is headquartered in Menlo Park, California. " (8/14/2018) 2. HC Wainwright analysts commented, "Our $13 12-month target is based on a DCF reflecting an 11.5% WACC discount and 1.5% terminal growth beyond fiscal 2026. Our model only explicitly includes the base-business, and U.S. partner revenue for the donepezil patch (launch 1Q20) and Twirla (launch calendar 2H19, but not in the stock now after partner setbacks). The donepezil patch has IP to 2037 and Twirla has issued patents to 2028." (8/13/2018) 3. Cantor Fitzgerald analysts commented, ": We reiterate our Overweight rating and $14 12-month PT for CORI stock. We maintain our belief that the donepezil Corplex patch will become an important new method for delivering a mainstay Alzheimer’s disease (AD) symptomatic treatment. We view successful development as a meaningful turning point in the company’s evolution and believe the investor base could broaden thereafter. Visibility as to other pipeline candidates could be an important driver of incremental share value too." (8/10/2018) Has Corium International been receiving favorable news coverage? Press coverage about CORI stock has trended somewhat positive this week, InfoTrie Sentiment reports. InfoTrie scores the sentiment of press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Corium International earned a media sentiment score of 2.0 on InfoTrie's scale. They also assigned news headlines about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the company's share price in the next several days. Who are some of Corium International's key competitors? Some companies that are related to Corium International include Zogenix (ZGNX), Innoviva (INVA), Madrigal Pharmaceuticals (MDGL), Reata Pharmaceuticals (RETA), Prestige Consumer Healthcare (PBH), PTC Therapeutics (PTCT), Mallinckrodt (MNK), Theravance Biopharma (TBPH), The Medicines (MDCO), Cambrex (CBM), Biohaven Pharmaceutical (BHVN), Enanta Pharmaceuticals (ENTA), Wave Life Sciences (WVE), Vanda Pharmaceuticals (VNDA) and Esperion Therapeutics (ESPR). Who are Corium International's key executives? Corium International's management team includes the folowing people: Mr. Peter D. Staple, Pres, CEO & Director (Age 66)Mr. Robert S. Breuil, Chief Financial Officer (Age 56)Dr. Parminder Singh, CTO & VP of R&D (Age 54)Mr. Timothy D. Sweemer CPA, Chief Accounting Officer, VP of Admin. & Sec.Ms. Christina Dickerson, VP of Corp. Devel. Who are Corium International's major shareholders? Corium International's stock is owned by many different of institutional and retail investors. Top institutional investors include AWM Investment Company Inc. (6.25%), BlackRock Inc. (6.19%), Franklin Resources Inc. (5.70%), Vanguard Group Inc. (3.98%), Opaleye Management Inc. (1.52%) and Gilder Gagnon Howe & Co. LLC (0.92%). Company insiders that own Corium International stock include Healthcare Master Fun Broadfin, Holding Co Gurnet, Joseph J Sarret, Life Sciences Maste Perceptive, Parminder Singh, Perceptive Advisors Llc, Peter D Staple, Robert S Breuil, Robert Thomas and Timothy D Sweemer. View Institutional Ownership Trends for Corium International. Which institutional investors are selling Corium International stock? CORI stock was sold by a variety of institutional investors in the last quarter, including Gilder Gagnon Howe & Co. LLC, Opaleye Management Inc., Renaissance Technologies LLC, AWM Investment Company Inc., Veritable L.P., Citadel Advisors LLC, Credit Suisse AG and Vanguard Group Inc.. Company insiders that have sold Corium International company stock in the last year include Joseph J Sarret, Life Sciences Maste Perceptive, Parminder Singh, Peter D Staple, Robert S Breuil, Robert Thomas and Timothy D Sweemer. View Insider Buying and Selling for Corium International. Which institutional investors are buying Corium International stock? CORI stock was bought by a variety of institutional investors in the last quarter, including Bamco Inc. NY, Bridgeway Capital Management Inc., Fosun International Ltd, Candriam Luxembourg S.C.A., BlackRock Inc., Private Capital Advisors Inc., Man Group plc and SG Americas Securities LLC. Company insiders that have bought Corium International stock in the last two years include Holding Co Gurnet, Life Sciences Maste Perceptive and Perceptive Advisors Llc. View Insider Buying and Selling for Corium International. How do I buy shares of Corium International? Shares of CORI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Corium International's stock price today? One share of CORI stock can currently be purchased for approximately $12.68. How big of a company is Corium International? Corium International has a market capitalization of $459.65 million and generates $31.86 million in revenue each year. The biopharmaceutical company earns $-47,790,000.00 in net income (profit) each year or ($1.64) on an earnings per share basis. Corium International employs 213 workers across the globe. What is Corium International's official website? The official website for Corium International is http://www.coriumgroup.com. How can I contact Corium International? Corium International's mailing address is 235 CONSTITUTION DRIVE, MENLO PARK CA, 94025. The biopharmaceutical company can be reached via phone at 650-298-8255 or via email at [email protected] MarketBeat Community Rating for Corium International (NASDAQ CORI)Community Ranking: 2.8 out of 5 ( )Outperform Votes: 287 (Vote Outperform)Underperform Votes: 227 (Vote Underperform)Total Votes: 514MarketBeat's community ratings are surveys of what our community members think about Corium International and other stocks. Vote "Outperform" if you believe CORI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CORI will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 12/13/2018 by MarketBeat.com StaffFeatured Article: What are different types of coverage ratios?